Biogen Idec and Elan won an important endorsement for Tysabri with a recommendation from Britain's cost-effectiveness watchdog--the National Institute for Health and Clinical Excellence--that the drug be made available to patients with the most severe form of the disease. Tysabri has been making a steady comeback [1] since the therapy was derailed in early '05 after patients taking the drug developed a rare brain disease. Regulators ushered it back onto the market after adding some restrictive guidelines on its use after a large contingent of MS patients demanded access to the therapy.
- check out the release [2]
- read the report [3] from the Irish Times
Related Articles:
FDA committee backs Tysabri for Crohn's [4]
After reintroduction, Tysabri builds patient base [1]
FDA allows Tysabri back on market [5]
Links:
[1] http://www.fiercebiotech.com/story/after-reintroduction-tysabri-builds-patient-base/2007-07-23
[2] http://www.fiercebiotech.com/press-releases/press-release-tysabri-demonstrates-significant-health-related-quality-life-improvem-0
[3] http://www.ireland.com/newspaper/breaking/2007/0822/breaking14.htm
[4] http://www.fiercebiotech.com/story/fda-committee-backs-tysabri-crohns/2007-08-01
[5] http://www.fiercebiotech.com/story/fda-allows-tysabri-back-on-market/2006-06-06